Status and phase
Conditions
Treatments
About
Primary object : Evaluate pharmacokinetic property AG1502 and Candesartan 32mg and Atorvastatin 40mg in healthy male subjects.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
60 participants in 2 patient groups
Loading...
Central trial contact
JINHYUNG KIM
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal